FDA Approves Vagus Nerve Stimulator for Rheumatoid Arthritis Treatment

July 31, 2025 - The FDA has approved a vagus nerve stimulation device developed by SetPoint Medical for treating moderate-to-severe rheumatoid arthritis in patients unresponsive to biologic or targeted synthetic DMARDs. Implanted in the neck and activated for one minute daily, the device showed clinical benefits in a year-long trial, with plans for U.S. commercialization beginning in select US cities in late 2025. (Source: Medscape)